Reuters logo
BRIEF-Sensorion says Oral SENS-401 prevents cisplatin-induced hearing loss by over 50 pct in preclinical study
September 12, 2017 / 7:44 AM / 2 months ago

BRIEF-Sensorion says Oral SENS-401 prevents cisplatin-induced hearing loss by over 50 pct in preclinical study

Sept 12 (Reuters) - SENSORION SA:

* SAID ON MONDAY, ORAL SENS-401 PREVENTED CISPLATIN-INDUCED HEARING LOSS BY MORE THAN 50 PERCENT IN PRECLINICAL STUDY

* DATA IN PEER-REVIEWED OTOLOGY & NEUROTOLOGY SUPPORTS SENS-401 ORPHAN DRUG DESIGNATION FOR PREVENTION OF PLATINUM-INDUCED OTOTOXICITY IN PEDIATRIC PATIENTS

Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below